Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  eflornithine
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: CPP-FAP-310, NCI-2013-01805, NCT01483144
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: NMTRC010, NCI-2015-01871, NCT02139397
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: NMTRC 003, NCI-2014-02153, NCI-2014-00474, NCT01586260
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 21 and under
Trial IDs: NMTRC003B, NCI-2015-01071, NCT02395666
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 29
Trial IDs: N2012-01, NCI-2015-00641, P01CA081403, NCT02030964
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Phase: Phase I
Type: Treatment
Age: 1 to 21
Trial IDs: NMTRC012, NCI-2015-01822, NCT02559778
Start Over